Online citations, reference lists, and bibliographies.
← Back to Search

Antitumor Activity Of IHL-305, A Novel Pegylated Liposome Containing Irinotecan, In Human Xenograft Models.

T. Matsuzaki, A. Takagi, T. Furuta, Satoshi Ueno, A. Kurita, G. Nohara, Hiroshi Kodaira, S. Sawada, S. Hashimoto
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The antitumor effect of IHL-305, a novel pegylated liposome containing irinotecan, was investigated in human xenograft models. After subcutaneous transplantation of several human cancer cell lines (colorectal, non-small cell lung, small cell lung, prostate, ovarian and gastric cancer cells) to nude mice, IHL-305 or CPT-11 was administered intravenously 3 times at 4-day intervals. In all xenograft models tested, IHL-305 showed superior antitumor activity to that of CPT‑11 and a comparable tumor-growth-inhibitory effect at one-eighth or less of the dose of CPT-11, even against HT-29 colorectal and NCI-H460 non-small cell lung cancer cell lines, which show intrinsic resistance to CPT-11. A single injection or 2 injections of IHL-305 on several dosing schedules also resulted in a significant antitumor effect compared to that of vehicle control in a dose-dependent manner and showed comparable antitumor activity at about one-fifth the dose of the maximum tolerated dose of CPT-11. The analysis of the concentrations of irinotecan and SN-38, an active metabolite of CPT-11, in plasma and tumors revealed that irinotecan was maintained at high concentrations, and the prolonged presence of SN-38 in plasma and tumors in IHL-305 treated mice compared with CPT-11-treated mice. Therefore, the stronger tumor inhibitory effect of IHL-305, as compared to CPT-11, was associated with the difference in the concentration of irinotecan in plasma or tumors after each agent was administered and with the maintainance of a higher concentration of SN-38. These results indicate that IHL-305 demonstrated superior antitumor activity against a wide range of tumors at lower doses than CPT-11.
This paper references
10.1158/1078-0432.CCR-0913-3
Therapeutic Synergy Between Irinotecan and 5-Fluorouracil against Human Tumor Xenografts
R. Azrak (2004)
10.1016/S0959-8049(99)00150-1
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.
T. André (1999)
10.1016/S0378-4347(98)00554-4
High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT.
A. Kurita (1999)
10.1016/J.IJPHARM.2003.09.050
Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME).
T. Tanaka (2004)
10.1111/j.1349-7006.1999.tb00737.x
Effective Irinotecan (CPT‐11)‐containing Liposomes: Intraliposomal Conversion to the Active Metabolite SN‐38
Y. Sadzuka (1999)
Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.
T. Kunimoto (1987)
10.1056/NEJM200009283431302
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
L. Saltz (2000)
10.1007/BF00264196
Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice
T. Matsuzaki (2004)
10.1211/jpp.57.10.0001
Drug delivery to tumours: recent strategies
L. H. Reddy (2005)
10.1111/j.1349-7006.2002.tb01217.x
Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil)
Y. Tsukioka (2002)
10.1007/BF00685508
Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice
Y. Kawato (2004)
10.1200/JCO.2002.03.123
Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.
E. Raymond (2002)
10.1002/(SICI)1097-0215(19970127)70:3<335::AID-IJC15>3.0.CO;2-E
CPT‐11 in human colon‐cancer cell lines and xenografts: Characterization of cellular sensitivity determinants
W. Jansen (1997)
10.1159/000089992
Combination of Irinotecan (CPT-11) plus 5-Fluorouracil and Leucovorin (FOLFIRI Regimen) as First Line Treatment for Elderly Patients with Metastatic Colorectal Cancer: A Phase II Trial
J. Souglakos (2005)
10.1097/01.coc.0000224542.80581.46
Phase I Study of Pegylated Liposomal Doxorubicin in Combination With Ifosfamide in Pretreated Ovarian Cancer Patients
H. Bourgeois (2006)
10.1056/NEJM200101253440413
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
M. Vaiani (2001)
10.1023/A:1013033826974
Preferential Binding of Polyethylene Glycol-Coated Liposomes Containing a Novel Cationic Lipid, TRX-20, to Human Subendthelial Cells via Chondroitin Sulfate
T. Harigai (2004)
10.1016/S0304-3835(98)00031-7
Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11.
Y. Sadzuka (1998)
10.1016/S0168-3659(99)00166-2
Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes.
P. Crosasso (2000)
10.1023/A:1018994111594
Novel Taxol Formulations: Preparation and Characterization of Taxol-Containing Liposomes
Amarnath Sharma (2004)
Izrael V and de Gramon A: CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuousinfusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer
T André (1999)
Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation.
A. Pal (2005)
10.1093/JNCI/78.4.707
Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38.
E. Mayhew (1987)
10.1007/0-306-47932-X_2
Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS.
J. Fang (2003)
10.1002/IJC.2910510618
Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes
J. Vaage (1992)
10.1097/00001813-200409000-00006
Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice
Sabrina Lei (2004)
Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo.
C. M. Lee (2002)
In vitro antitumor effect of topoisomerase-I inhibitor, CPT-11, on freshly isolated human gastric and colorectal cancer.
T. Tsunoda (1999)
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
A. Gabizon (1994)
10.1097/01.coc.0000217552.69036.16
Phase I-II Study of Pegylated Liposomal Doxorubicin Combined With Weekly Paclitaxel as First-Line Treatment in Patients With Metastatic Breast Cancer
H. Bourgeois (2006)
10.1016/S0959-8049(98)00423-7
CPT-11 in gastrointestinal cancer.
H. Bleiberg (1999)
10.1016/J.CTRV.2004.05.002
New approaches to prevent intestinal toxicity of irinotecan-based regimens.
A. Alimonti (2004)
10.1007/BF00262744
Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo
T. Tsuruo (2004)
10.1248/CPB.39.1446
Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin.
S. Sawada (1991)
10.1002/IJC.2910510221
Pharmacokinetics and antitumor activity of epirubicin encapsulated in long‐circulating liposomes incorporating a polyethylene glycol‐derivatized phospholipid
E. Mayhew (1992)



This paper is referenced by
10.1007/978-981-13-7607-8
Bioactive Natural Products for the Management of Cancer: from Bench to Bedside
Anil K. Sharma (2019)
10.1007/s00280-014-2577-7
Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models
U. Hoch (2014)
10.1016/j.ejpb.2015.03.018
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Edgar Pérez-Herrero (2015)
NANOCARRIERS: AS POTENTIAL TARGETED DRUG DELIVERY SYSTEMS FOR CANCER THERAPY
Mercy Sulochana (2016)
10.5958/2231-5713.2015.00008.2
A Review- Emerging Use of Nano-Based Carriers in Diagnosis and Treatment of Cancer-Novel Approaches
Yaqub Khan (2015)
10.1007/s00228-013-1580-y
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors
H. Wu (2013)
10.1186/1471-2407-12-462
PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse
H. Konishi (2012)
10.1021/nn501162x
Hyperthermia-mediated local drug delivery by a bubble-generating liposomal system for tumor-specific chemotherapy.
Ko-Jie Chen (2014)
Nanotechnology in Drug Delivery 21 2 Role of nanoparticles in targeted drug delivery system
Sonali Pardhiya (2016)
10.3390/ph6111361
Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes
Mónica Rivera Díaz (2013)
10.1007/978-981-13-7607-8_9
Drug Resistance in Cancer and Role of Nanomedicine-Based Natural Products
Deeptashree Nandi (2019)
NANO TECHNICAL TRENDS FOR CANCER TREATMENT: QUANTUM DOTs a SMART DRUG DELIVERY SYSTEM
Preet Amol Singh (2016)
10.1002/btm2.10166
Hyaluronic Acid‐Doxorubicin Nanoparticles for Targeted Treatment of Colorectal Cancer
Daniel C Pan (2020)
Semantic Scholar Logo Some data provided by SemanticScholar